Related Experiment Videos
[Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia in children]
1Service des explorations fonctionnelles respiratoires, hôpital Saint-Vincent-de-Paul, Paris, France.
Abstract:
Chlamydia pneumoniae and Mycoplasma pneumoniae are frequently involved in lower respiratory tract infections in children. Their responsibility must be evoked whenever an antibiotic treatment has been prescribed for a suspected bacterial origin, without clinical improvement (persistent fever particularly) after 48 hours. This must lead to the prescription of a macrolide.
Insights
Persistent fever in children with suspected bacterial pneumonia unresponsive to initial antibiotics suggests Chlamydia pneumoniae or Mycoplasma pneumoniae infection. Prompt macrolide prescription is recommended for effective treatment.
Area of Science:
- Pediatric infectious diseases
- Respiratory medicine
- Microbiology
Context:
- Lower respiratory tract infections (LRTI) are common in children.
- Bacterial pathogens are often suspected as the cause of pediatric LRTI.
- Initial antibiotic therapy may fail to resolve symptoms in some cases.
Purpose:
- To highlight the role of specific atypical bacteria in pediatric LRTI.
- To provide guidance on identifying treatment-resistant cases.
- To recommend appropriate antimicrobial therapy for persistent infections.
Summary:
- Chlamydia pneumoniae and Mycoplasma pneumoniae are significant contributors to pediatric lower respiratory tract infections.
- Persistent fever exceeding 48 hours despite antibiotics for suspected bacterial pneumonia warrants consideration of these pathogens.
- Macrolide antibiotics are the recommended treatment for Chlamydia pneumoniae and Mycoplasma pneumoniae infections.
Impact:
- Improved diagnostic suspicion for atypical pneumonia in children.
- Reduced time to effective antibiotic treatment, potentially shortening illness duration.
- Optimized antibiotic stewardship by guiding therapy for treatment failures.